L01A Alkylating agents L01AA Nitrogen mustard analogues L01AA01 Cyclophosphamide L01AA02 Chlorambucil L01AA03 Melphalan L01AA05 Chlormethine L01AA06 Ifosfamide L01AA07 Trofosfamide L01AA08 Prednimustine L01AA09 Bendamustine L01AA10 Melphalan flufenamide L01AB Alkyl sulfonates L01AB01 Busulfan L01AB02 Treosulfan L01AB03 Mannosulfan L01AC Ethylene imines L01AC01 Thiotepa L01AC02 Triaziquone L01AC03 Carboquone L01AD Nitrosoureas L01AD01 Carmustine L01AD02 Lomustine L01AD03 Semustine L01AD04 Streptozocin L01AD05 Fotemustine L01AD06 Nimustine L01AD07 Ranimustine L01AD08 Uramustine L01AG Epoxides L01AG01 Etoglucid L01AX Other alkylating agents L01AX01 Mitobronitol L01AX02 Pipobroman L01AX03 Temozolomide L01AX04 Dacarbazine L01B Antimetabolites L01BA Folic acid analogues L01BA01 Methotrexate L01BA03 Raltitrexed L01BA04 Pemetrexed L01BA05 Pralatrexate L01BB Purine analogues L01BB02 Mercaptopurine L01BB03 Tioguanine L01BB04 Cladribine L01BB05 Fludarabine L01BB06 Clofarabine L01BB07 Nelarabine QL01BB90 Rabacfosadine L01BC Pyrimidine analogues L01BC01 Cytarabine L01BC02 Fluorouracil L01BC03 Tegafur L01BC04 Carmofur L01BC05 Gemcitabine L01BC06 Capecitabine L01BC07 Azacitidine L01BC08 Decitabine L01BC09 Floxuridine L01BC52 Fluorouracil, combinations L01BC53 Tegafur, combinations L01BC59 Trifluridine, combinations L01C Plant alkaloids and other natural products L01CA Vinca alkaloids and analogues L01CA01 Vinblastine L01CA02 Vincristine L01CA03 Vindesine L01CA04 Vinorelbine L01CA05 Vinflunine L01CA06 Vintafolide L01CB Podophyllotoxin derivatives L01CB01 Etoposide L01CB02 Teniposide L01CC Colchicine derivatives L01CC01 Demecolcine L01CD Taxanes L01CD01 Paclitaxel L01CD02 Docetaxel L01CD03 Paclitaxel poliglumex L01CD04 Cabazitaxel L01CD51 Paclitaxel and encequidar L01CE Topoisomerase 1 (TOP1) inhibitors L01CE01 Topotecan L01CE02 Irinotecan L01CE03 Etirinotecan pegol L01CE04 Belotecan L01CX Other plant alkaloids and natural products L01CX01 Trabectedin L01D Cytotoxic antibiotics and related substances L01DA Actinomycines L01DA01 Dactinomycin L01DB Anthracyclines and related substances L01DB01 Doxorubicin L01DB02 Daunorubicin L01DB03 Epirubicin L01DB04 Aclarubicin L01DB05 Zorubicin L01DB06 Idarubicin L01DB07 Mitoxantrone L01DB08 Pirarubicin L01DB09 Valrubicin L01DB10 Amrubicin L01DB11 Pixantrone L01DC Other cytotoxic antibiotics L01DC01 Bleomycin L01DC02 Plicamycin L01DC03 Mitomycin L01DC04 Ixabepilone L01E Protein kinase inhibitors L01EA BCR-ABL tyrosine kinase inhibitors L01EA01 Imatinib L01EA02 Dasatinib L01EA03 Nilotinib L01EA04 Bosutinib L01EA05 Ponatinib L01EA06 Asciminib L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors L01EB01 Gefitinib L01EB02 Erlotinib L01EB03 Afatinib L01EB04 Osimertinib L01EB05 Rociletinib L01EB06 Olmutinib L01EB07 Dacomitinib L01EB08 Icotinib L01EB09 Lazertinib L01EB10 Mobocertinib L01EB11 Aumolertinib L01EC B-Raf serine-threonine kinase (BRAF) inhibitors L01EC01 Vemurafenib L01EC02 Dabrafenib L01EC03 Encorafenib L01ED Anaplastic lymphoma kinase (ALK) inhibitors L01ED01 Crizotinib L01ED02 Ceritinib L01ED03 Alectinib L01ED04 Brigatinib L01ED05 Lorlatinib L01EE Mitogen-activated protein kinase (MEK) inhibitors L01EE01 Trametinib L01EE02 Cobimetinib L01EE03 Binimetinib L01EE04 Selumetinib L01EF Cyclin-dependent kinase (CDK) inhibitors L01EF01 Palbociclib L01EF02 Ribociclib L01EF03 Abemaciclib L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors L01EG01 Temsirolimus L01EG02 Everolimus L01EG03 Ridaforolimus L01EG04 Sirolimus L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors L01EH01 Lapatinib L01EH02 Neratinib L01EH03 Tucatinib